The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
AMRN with a SLAM DUNK FDA approval and the positive list of pipeline drug including the one which just received patent approval is a great target for buyout. Also noting that AMRN will increase it's buyout price after the FDA approval from $22.50 which was offered by Bristol Myers last year. Long and strong $30 pps.